FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1826995994> ?p ?o ?g. }

• W1826995994 endingPage "68" @default.
• W1826995994 startingPage "2859" @default.
• W1826995994 abstract "We describe here the in vitro and in vivo antileukemia activity of a recently described natural killer (NK) cell line (NK-92), which has features of human activated NK cells. The cytotoxic activity of rhIL2-dependent cultured NK-92 cells against primary patient-derived leukemic target cells [12 acute myelogenous leukemias (AMLs), 7 T acute lymphoblastic leukemias (T-ALLs), 14 B-lineage-ALLs, and 13 chronic myelogenous leukemias (CMLs)], human leukemic cell lines (K562, KG1, HL60, Raji, NALM6, TALL-104, CEM-S, and CEM-T) and normal bone marrow cells was measured in 51Cr-release assay (CRA). The patient-derived leukemias could be subdivided into three groups based on their sensitivity to NK-92 cells: insensitive (< or =19% lysis), sensitive (20-49% lysis), and highly sensitive (> or =50% lysis) at an E:T ratio of 9:1. Of 46 patient-derived samples, 24 (52.2%) were sensitive or highly sensitive to NK-92-mediated in vitro cytotoxicity (6 of 12 AMLs, 7 of 7 T-ALLs, 5 of 14 B-lineage-ALLs, and 6 of 13 CMLs). NK-92 cells were highly cytotoxic against all of the eight leukemic cell lines tested in a standard 4-h CRA. Normal human bone marrow hematopoietic cells derived from 18 normal donors were insensitive to NK-92-mediated cytolysis. In comparison with human lymphokine-activated killer cells, normal NK cells, and T cells, NK-92 cells displayed more powerful antileukemia activity against a patient-derived T-ALL as well as K562 and HL60 cells, both in in vitro CRA and in a xenografted human leukemia SCID mouse model. The NK-92 cells did not induce the development of leukemia in SCID mice after i.v., i.p., or s.c. inoculation. In adoptive transfer experiments, SCID mice receiving i.p. inoculations of human leukemias derived from a T-ALL (TA27) and an AML (MA26) that were highly sensitive to the cytolysis of NK-92 cells in vitro, as well as a pre-B-ALL (BA31) that was insensitive to the in vitro cytolysis of NK-92 cells, were treated by administration of NK-92 cells with or without rhIL2 (2 x 10(7) NK-92 cells i.p.; one dose or five doses). Survival times of SCID mice bearing the sensitive TA27 and MA26 leukemias were significantly prolonged by adoptive cell therapy with NK-92 cells. Some of the animals who received five doses of NK-92 cells with or without rhIL2 administration were still alive without any signs of leukemia development 6 months after leukemia inoculation. In contrast, survival of mice bearing the insensitive BA31 leukemia were not affected by this treatment. This in vitro and in vivo antileukemia effect of NK-92 cells suggests that cytotoxic NK cells of this type may have potential as effectors of leukemia control." @default.
• W1826995994 created "2016-06-24" @default.
• W1826995994 creator A5030178053 @default.
• W1826995994 creator A5034653175 @default.
• W1826995994 creator A5047653645 @default.
• W1826995994 creator A5048411184 @default.
• W1826995994 creator A5058476408 @default.
• W1826995994 creator A5072305208 @default.
• W1826995994 creator A5079265499 @default.
• W1826995994 date "1998-11-01" @default.
• W1826995994 modified "2023-09-23" @default.
• W1826995994 title "Antileukemia activity of a natural killer cell line against human leukemias." @default.
• W1826995994 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9829753" @default.
• W1826995994 hasPublicationYear "1998" @default.
• W1826995994 type Work @default.
• W1826995994 sameAs 1826995994 @default.
• W1826995994 citedByCount "56" @default.
• W1826995994 countsByYear W18269959942012 @default.
• W1826995994 countsByYear W18269959942015 @default.
• W1826995994 countsByYear W18269959942016 @default.
• W1826995994 countsByYear W18269959942017 @default.
• W1826995994 countsByYear W18269959942018 @default.
• W1826995994 countsByYear W18269959942019 @default.
• W1826995994 countsByYear W18269959942020 @default.
• W1826995994 countsByYear W18269959942021 @default.
• W1826995994 countsByYear W18269959942022 @default.
• W1826995994 countsByYear W18269959942023 @default.
• W1826995994 crossrefType "journal-article" @default.
• W1826995994 hasAuthorship W1826995994A5030178053 @default.
• W1826995994 hasAuthorship W1826995994A5034653175 @default.
• W1826995994 hasAuthorship W1826995994A5047653645 @default.
• W1826995994 hasAuthorship W1826995994A5048411184 @default.
• W1826995994 hasAuthorship W1826995994A5058476408 @default.
• W1826995994 hasAuthorship W1826995994A5072305208 @default.
• W1826995994 hasAuthorship W1826995994A5079265499 @default.
• W1826995994 hasConcept C109159458 @default.
• W1826995994 hasConcept C109316439 @default.
• W1826995994 hasConcept C129374314 @default.
• W1826995994 hasConcept C153911025 @default.
• W1826995994 hasConcept C154317977 @default.
• W1826995994 hasConcept C171122931 @default.
• W1826995994 hasConcept C202751555 @default.
• W1826995994 hasConcept C203014093 @default.
• W1826995994 hasConcept C206191192 @default.
• W1826995994 hasConcept C2778102761 @default.
• W1826995994 hasConcept C2778461978 @default.
• W1826995994 hasConcept C2778903051 @default.
• W1826995994 hasConcept C2780007613 @default.
• W1826995994 hasConcept C28328180 @default.
• W1826995994 hasConcept C28651165 @default.
• W1826995994 hasConcept C502942594 @default.
• W1826995994 hasConcept C54355233 @default.
• W1826995994 hasConcept C55493867 @default.
• W1826995994 hasConcept C73588182 @default.
• W1826995994 hasConcept C81885089 @default.
• W1826995994 hasConcept C86803240 @default.
• W1826995994 hasConcept C95444343 @default.
• W1826995994 hasConceptScore W1826995994C109159458 @default.
• W1826995994 hasConceptScore W1826995994C109316439 @default.
• W1826995994 hasConceptScore W1826995994C129374314 @default.
• W1826995994 hasConceptScore W1826995994C153911025 @default.
• W1826995994 hasConceptScore W1826995994C154317977 @default.
• W1826995994 hasConceptScore W1826995994C171122931 @default.
• W1826995994 hasConceptScore W1826995994C202751555 @default.
• W1826995994 hasConceptScore W1826995994C203014093 @default.
• W1826995994 hasConceptScore W1826995994C206191192 @default.
• W1826995994 hasConceptScore W1826995994C2778102761 @default.
• W1826995994 hasConceptScore W1826995994C2778461978 @default.
• W1826995994 hasConceptScore W1826995994C2778903051 @default.
• W1826995994 hasConceptScore W1826995994C2780007613 @default.
• W1826995994 hasConceptScore W1826995994C28328180 @default.
• W1826995994 hasConceptScore W1826995994C28651165 @default.
• W1826995994 hasConceptScore W1826995994C502942594 @default.
• W1826995994 hasConceptScore W1826995994C54355233 @default.
• W1826995994 hasConceptScore W1826995994C55493867 @default.
• W1826995994 hasConceptScore W1826995994C73588182 @default.
• W1826995994 hasConceptScore W1826995994C81885089 @default.
• W1826995994 hasConceptScore W1826995994C86803240 @default.
• W1826995994 hasConceptScore W1826995994C95444343 @default.
• W1826995994 hasIssue "11" @default.
• W1826995994 hasLocation W18269959941 @default.
• W1826995994 hasOpenAccess W1826995994 @default.
• W1826995994 hasPrimaryLocation W18269959941 @default.
• W1826995994 hasRelatedWork W12044261 @default.
• W1826995994 hasRelatedWork W1690910326 @default.
• W1826995994 hasRelatedWork W1826995994 @default.
• W1826995994 hasRelatedWork W1976033765 @default.
• W1826995994 hasRelatedWork W1976175233 @default.
• W1826995994 hasRelatedWork W1977424931 @default.
• W1826995994 hasRelatedWork W1995414861 @default.
• W1826995994 hasRelatedWork W2000852068 @default.
• W1826995994 hasRelatedWork W2295246103 @default.
• W1826995994 hasRelatedWork W987809206 @default.
• W1826995994 hasVolume "4" @default.
• W1826995994 isParatext "false" @default.
• W1826995994 isRetracted "false" @default.
• W1826995994 magId "1826995994" @default.
• W1826995994 workType "article" @default.